GLP-1 Weight Loss: How to Prevent Regain and Maintain Long-Term Results

New research into glucagon-like peptide-1 (GLP-1) receptor agonists—the class of drugs including Ozempic and Wegovy—is highlighting the challenges of long-term weight maintenance and the potential risks of inconsistent dosing. While these medications have transformed the treatment of obesity and type 2 diabetes, clinicians are increasingly focused on the weight rebound that often occurs after patients discontinue the therapy.

Recent findings suggest that the strategy of stopping and restarting these medications to manage weight may be counterproductive. A preclinical study from researchers at the Perelman School of Medicine at the University of Pennsylvania, published in the Journal of Clinical Investigation Insight, found that inconsistent use of certain GLP-1s could significantly reduce their effectiveness. The study observed that overweight mice dropped progressively less weight each time they stopped and restarted the medication compared to their initial weight loss.

The Challenge of Weight Rebound

The phenomenon of weight regain after stopping GLP-1 drugs is a widespread concern in clinical practice. Some estimates suggest that up to 70% of people who discontinue these medications experience weight rebound, often regaining their lost weight within 18 months.

This trend has led researchers to seek an off-ramp for patients who cannot or do not wish to remain on long-term medication. The goal is to find a way to preserve the metabolic benefits of the drugs without requiring lifelong injections.

A Potential ‘Gut Reset’ Solution

To address this, a trial led by Dartmouth Health is testing a minimally invasive outpatient procedure known as duodenal mucosal resurfacing (DMR). This procedure, which is already used to treat type 2 diabetes, acts as a gut reset by using heat to remove damaged tissue from the inner lining of the duodenum, the part of the small intestine where many GLP-1-related hormones are produced.

Initial results from the REMAIN-1 trial, presented at Digestive Disease Week 2026, indicate that a single DMR procedure helped maintain weight loss for up to six months after adults with obesity stopped their GLP-1 medications. Some reports suggest the procedure could help patients retain as much as 80% of their weight loss.

“Finding a treatment that allows patients to stop these medications without weight regain or loss of metabolic benefit is a huge unmet need.”Shelby Sullivan, MD, professor of medicine at Dartmouth

Dr. Sullivan noted that the benefit of the procedure appears to increase over time rather than fade, suggesting that the treatment targets the correct biological mechanisms. She stated that if these results are validated in the full trial, the procedure could fundamentally change how we think about GLP-1 therapy.

Clinical Context and Future Outlook

These developments underscore a shift in how medical professionals view GLP-1 therapies, moving away from seeing them as quick fixes and toward treating obesity as a chronic condition requiring long-term management. The American Association of Clinical Endocrinology (AACE) has advocated for complication-centric care, placing GLP-1 receptor agonists at the top of the preferred medication list for obesity complications.

While the duodenal mucosal resurfacing procedure offers a promising alternative for weight maintenance, researchers emphasize that This proves currently an investigational therapy. Further data from the full REMAIN-1 trial will be necessary to confirm its long-term efficacy and safety before it becomes a standard part of obesity care.